84539-30-0

Basic information

• Product Name: 5-BROMO-N-METHYLPYRIDIN-2-AMINE
• Synonyms: 5-BROMO-N-METHYLPYRIDIN-2-AMINE;5-Bromo-2-(N-methylamino)pyridine;5-bromo-N-methyl-2-pyridinamine(SALTDATA: FREE);2-(Methylamino)-5-bromopyridine;N-Methyl-5-bromopyridine-2-amine;2-PyridinaMine, 5-broMo-N-Methyl-
• CAS NO: 84539-30-0
• Molecular Formula: C₆H₇BrN₂
• Molecular Weight: 187.04
• Mol File: 84539-30-0.mol

Chemical Properties

• Melting Point: 70-71 °C
• Boiling Point: 245℃
• Flash Point: 102℃
• Appearance: /
• Density: 1.581
• Storage Temp.: Room temperature.
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 5.00±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-N-METHYLPYRIDIN-2-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-N-METHYLPYRIDIN-2-AMINE(84539-30-0)
• EPA Substance Registry System: 5-BROMO-N-METHYLPYRIDIN-2-AMINE(84539-30-0)

Safety Data

• RIDADR: UN2811
• HazardClass: IRRITANT
• Hazardous Substances Data: 84539-30-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-N-methylpyridin-2-amine is used as a synthetic intermediate for the preparation of halo aminopyridines, which are important building blocks in the development of various pharmaceuticals. These halo aminopyridines can be further modified to create a wide range of therapeutic agents with diverse applications, such as antibiotics, antivirals, and anticancer drugs.
Used in Agrochemical Industry:
In the agrochemical industry, 5-Bromo-N-methylpyridin-2-amine serves as a key intermediate in the synthesis of various agrochemicals, including herbicides, insecticides, and fungicides. The unique properties of 5-Bromo-N-methylpyridin-2-amine allow for the development of effective and targeted pest control solutions, contributing to improved crop yields and food security.
Overall, 5-Bromo-N-methylpyridin-2-amine is a versatile and valuable compound in both the pharmaceutical and agrochemical industries, playing a crucial role in the synthesis of a variety of life-saving and crop-protecting agents.

InChI:InChI=1S/C6H7BrN2/c1-8-6-3-2-5(7)4-9-6/h2-4H,1H3,(H,8,9)

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 74-89-5 methylamine 
• 1072-97-5 5-bromo-2-pyridylamine 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 53939-30-3 5-bromo-2-chloropyridine 
• 593-51-1 methylamine hydrochloride 
• 4597-87-9 2-(N-methylamino)pyridine 
• 766-11-0 5-bromo-2-fluoropyridine 
• 157020-26-3 pyridinium N-<2'-(5'-bromopyridyl)>aminide 
• 28539-02-8 1-Hydroxymethyl-1H-benzotriazole 

Downstream Products

• 1005009-98-2 methyl-[5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)pyridin-2-yl]amine 
• 1360551-68-3 2-[4-(3-{(R)-1-cyclopropyl-1-[4-(6-methylamino-pyridin-3-yl)-phenyl]-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide 
• 1360551-39-8 2-[4-(3-{1-cyclopropyl-1-[4-(6-methylamino-pyridin-3-yl)-phenyl]-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide 
• 1613168-96-9 4-(6-(methylamino)pyridin-3-yl)phenol 
• 1613169-20-2 ethyl 2-(4-(6-(methylamino)pyridin-3-yl)phenoxy)acetate 
• 1032758-87-4 methyl-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-2-yl]-carbamic acid tert-butyl ester 
• 1235449-52-1 N-hydroxy-2-(methyl((2-(6-(methylamino)pyridin-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)amino)pyrimidine-5-carboxamide 
• 261715-36-0 6-(methylamino)nicotinonitrile 
• 1267851-49-9 N-(5-tert-butylisoxazol-3-yl)-2-(4-(6-(methylamino)pyridin-3-yl)phenyl)acetamide 
• 227939-01-7 5-bromo-2-(N-methyl-N-(t-butoxycarbonyl)amino)pyridine 
• 152684-20-3 N-methyl-3-nitro-5-phenylpyridin-2-amine 

Relevant articles and documents

Directing Group Enables Electrochemical Selectively Meta-Bromination of Pyridines under Mild Conditions

Without the use of catalysts and oxidants, a facile and sustainable electrochemical bromination protocol was developed. By introducing the directing groups, the regioselectivity of pyridine derivatives could be controlled at themeta-position utilizing the inexpensive and safe bromine salts at room temperature. A variety of brominated pyridine derivatives were obtained in 28-95% yields, and the reaction could be readily performed at a gram scale. By combining the installation and removing the directing group, the concept ofmeta-bromination of pyridines could be verified.

Thiophene pyrimidines and preparation and its preparation method and application

The invention discloses a pyrantel compound and preparation, as well as a preparation method and application of the pyrantel compound and preparation, belonging to the technical field of chemical medicines and preparations thereof. According to the pyrantel compound or pharmaceutically acceptable salt thereof, HDAC (histone deacetylase)/PI3K (phosphatidylinositide 3-kinase) double-target inhibitor is used for selectively inhibiting tumor cell messenger core protein kinase target PI3K and epigenetic target HDAC which are synergized, and is capable of destroying the network of tumor cell messengers, thus exerting a great killing effect on various tumor cells. In multiple blood and entity heterogenic transplanted tumor animal models, the inhibitor can be used for intensively effectively inhibiting tumor growth and especially has a remarkable effect on various blood B-cell malignant tumors, and safety evaluation tests indicate that the inhibitor has high safety and security. The pyrantel compound and preparation can be used for effectively treating patients with later reoccurrence of lymphoma, myeloma and lymphatic leukemia or drug resistance.

Mono-N-methylation of anilines with methanol catalyzed by a manganese pincer-complex

The selective mono-N-methylation of anilines derivatives was achieved under mild conditions using inexpensive methanol as C1 source. Under hydrogen borrowing conditions, using a tridentate PN3P manganese pre-catalyst (5?mol%), a catalytic amount of base (20?mol%), for 24?h at 120?°C, a large variety of anilines derivatives was methylated in good to excellent yield. Mechanistic investigations allowed us to isolate and characterize by X-ray diffraction studies a de-aromatized manganese intermediate.

IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES

Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY

The present invention relates to combination therapy using compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein and an additional pharmaceutically active agent. The invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations in the treatment of various diseases and disorders.

Tetrahydroquinoline Derivatives And Their Pharmaceutical Use

Tetrahydroquinoline compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE

Tetrahydroquinoline compounds of Formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds

Provided herein are hepatitis C virus entry inhibitor oxoacetamide compounds, pharmaceutical compositions thereof, and methods for their use in treatment or prevention of hepatitis C virus infection in a subject in need thereof.

Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2

5-(Hetero)aryl-3-(4-carboxamidophenyl)-2-aminopyridine inhibitors of CHK2 were identified from high throughput screening of a kinase-focussed compound library. Rapid exploration of the hits through straightforward chemistry established structure-activity relationships and a proposed ATP-competitive binding mode which was verified by X-ray crystallography of several analogues bound to CHK2. Variation of the 5-(hetero)aryl substituent identified bicyclic dioxolane and dioxane groups which improved the affinity and the selectivity of the compounds for CHK2 versus CHK1. The 3-(4-carboxamidophenyl) substituent could be successfully replaced by acyclic ω-aminoalkylamides, which made additional polar interactions within the binding site and led to more potent inhibitors of CHK2. Compounds from this series showed activity in cell-based mechanistic assays for inhibition of CHK2.

NEW COMPOUNDS

The present invention encompasses compounds of general formula (1), wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use